Reports Q1: '329 Activity In Low Dose Cohorts Is Encouraging Ahead Of Q4 Update

Research evidence excerpt

Reports Q1: '329 Activity In Low Dose Cohorts Is Encouraging Ahead Of Q4 Update

Biotechnology

Allogene Therapeutics

TD SECURITIES (USA) LLC EARNINGS UPDATE

May 13, 2026

Price: $2.33 (05/13/2026) Reports Q1: '329 Activity In Low Dose Cohorts

Price Target: NA Is Encouraging Ahead Of Q4 Update

BUY (1)

ESG SCORE: 59/100

Tyler Van Buren THE TD COWEN INSIGHT

646 562 1343

We are more confident in ALPHA3's success following cema-cel's impressive +42% MRD benefit

tyler.vanburen@tdsecurities.com

reported in April. Enthusiasm for its profile and the global site expansion should continue to

Sam Rollenhagen fuel enrollment ahead of the expected YE 2027 completion. For '329, early signs of activity

212 468 7785 from low dose cohorts (incl. w/o LD) is encouraging, and so is the enrollment pace for a CAR-T

samuel.rollenhagen@tdsecurities.com

AID study. More data in Q4.

Nicholas Lorusso

646 562 1390 58% MRD Clearance In ALPHA3 Increases Confidence In Success

nick.lorusso@tdsecurities.com

Allogene is aiming to redefine the standard of care for 1L LBCL treatment with the ALPHA3

Greg W. Torres, Ph.D. trial, where it is positioning cema-cel as the effective 7th cycle of R-CHOP in MRD+ positive

646 562 1351

patients. Allogene reported the first clinical data from ALPHA3 in April, where cema-cel led

gregory.wiessner@tdsecurities.com

to a 58% MRD clearance rate (n=7/12) compared to a 17% rate with observation (n=2/12). This

Key Data 42% improvement in MRD clearance over observation convincingly surpassed the 25%+ bar

Symbol NASDAQ: ALLO established prior and significantly increased our confidence that cema-cel will achieve the 50%

Beta: 0.46 improvement in EFS needed to hit stats in the interim or primary analysis (expected mid-2027

52-Week Range: $3.06-$0.95 and mid-2028).